Envoy Medical (COCH) to Announce Earnings on Thursday

Envoy Medical (NASDAQ:COCH) is anticipated to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $0.10 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Envoy Medical (NASDAQ:COCH) last posted its earnings results on Monday, May 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. On average, analysts expect Envoy Medical to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Envoy Medical Stock Up 1.8%

Shares of COCH opened at $0.69 on Thursday. The company has a market capitalization of $53.27 million, a price-to-earnings ratio of -0.69 and a beta of 1.88. The stock’s 50-day moving average price is $0.69 and its 200-day moving average price is $0.69. Envoy Medical has a 52 week low of $0.36 and a 52 week high of $1.89.

Institutional Investors Weigh In On Envoy Medical

Hedge funds and other institutional investors have recently modified their holdings of the company. Focus Partners Wealth acquired a new stake in Envoy Medical in the first quarter valued at $276,000. Geode Capital Management LLC raised its position in Envoy Medical by 111.3% in the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock valued at $65,000 after purchasing an additional 51,813 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Envoy Medical in the 3rd quarter valued at about $60,000. 8.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on COCH shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a research report on Friday, April 24th. Zacks Research raised shares of Envoy Medical to a “hold” rating in a research report on Wednesday, April 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $2.50 target price on shares of Envoy Medical in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $2.50.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.